Cary Street Partners Investment Advisory’s abrdn Life Sciences Investors HQL Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,893	Closed	-$48.5K	–	1137
2023 Q3	$48.5K	Hold	3,893	–	–	﹤0.01%	878
2023 Q2	$52.7K	Hold	3,893	–	–	﹤0.01%	801
2023 Q1	$54.2K	Hold	3,893	–	–	﹤0.01%	726
2022 Q4	$55.3K	Buy	+3,893	New	+$56.4K	﹤0.01%	713

Other funds holding HQL

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cornerstone Advisors Asheville, North Carolina $2.72B AUM 22.17% 1-Year Est. Return

1CP

1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

CCP

Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return

RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Cary Street Partners Investment Advisory's HQL Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of abrdn Life Sciences Investors (HQL) in Q4 2023, closing a stake of 3,893 shares — an estimated $48.5K sold.

Cary Street Partners Investment Advisory first reported a position in HQL in Q4 2022 and held it in 4 quarters. The position peaked at $55.3K in Q4 2022. 79 funds tracked by Wall St. Rank hold HQL as of Q4 2023.

Cary Street Partners Investment Advisory reported no remaining abrdn Life Sciences Investors position as of Q4 2023 after selling out during the quarter.
Cary Street Partners Investment Advisory sold 3,893 abrdn Life Sciences Investors shares in Q4 2023, an estimated $48.5K.
Cary Street Partners Investment Advisory first reported a position in abrdn Life Sciences Investors in Q4 2022 and held it in 4 quarters.
Cary Street Partners Investment Advisory's abrdn Life Sciences Investors position peaked at $55.3K in Q4 2022.
79 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.